Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy

Annals of Hematology

Volumn 92, Issue 2, 2013, Pages 231-238

  Kim, Tark ^a   Choi, Sang Ho ^a   Kim, Sung Han ^a   Jeong, Jin Yong ^a   Woo, Jun Hee ^a   Kim, Yang Soo ^a   Sung, Heungsup ^a   Kim, Mi Na ^a   Yoon, Dok Hyun ^a   Suh, Cheolwon ^a   Lee, Sang Oh ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Non Hodgkin lymphoma; Pneumocystis pneumonia; Prevalence; R CHOP

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNGUS IDENTIFICATION; HUMAN; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; PREVALENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK; VINCRISTINE;

EID: 84872344552     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1592-1     Document Type: Article

References (25)

1. Sepkowitz KA, Brown AE, Armstrong D (1995) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155:1125-1128
2. Moon SM, Kim T, Sung H, Kim MN, Kim SH, Choi SH, Jeong JY, Woo JH, Kim YS, Lee SO (2011) Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients. Antimicrob Agents Chemother 55:4613-4618. doi: 10.1128/AAC.00669-11
3. Overgaard UM, Helweg-Larsen J (2007) Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 39:589-595. doi: 10.1080/00365540601150497
4. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D (1992) Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267:832-837
5. Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA (2005) An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. Br J Cancer 92:867-872. doi: 10.1038/sj.bjc.6602412
6. Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47:187-198. doi: 10.1053/j.seminhematol.2010.01.002
7. Kulke MH, Vance EA (1997) Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 25:215-218
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006. doi: 10.1056/NEJM199304083281404
9. Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM, Avivi I (2012) The Increased Risk for Pneumocystis Pneumonia in Patients Receiving Rituximab-CHOP-14 Can Be Prevented by the Administration of Trimethoprim/ Sulfamethoxazole: A Single-Center Experience. Acta Haematol 127:110-114. doi: 10.1159/000334113
10. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM (2011) Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol 22:149-155. doi: 10.1093/annonc/mdq314
11. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391. doi: 10.1016/S1470-2045(06)70664-7
12. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116. doi: 10.1016/S1470- 2045(08)70002-0
13. Chang H, Shih LY, Wang CW, Chuang WY, Chen CC (2010) Granulomatous Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Acta Haematol 123:30-33. doi: 10.1159/000261020
14. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R (2008) Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 80:275-276. doi: 10.1111/j.1600-0609. 2007.00994.x
15. Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH (2011) Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 90:1145-1151. doi: 10.1007/s00277-011-1268-2
16. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS (2010) High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 51:797-801. doi: 10.3109/10428191003699860
17. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D (2007) Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 92:139-140
18. Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS (2010) Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 25:86-92. doi: 10.3904/kjim.2010.25.1.86
19. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group (1989). Eur Respir J 2:561-585
20. Pfaller MA AE (2009) Pneumocystis. Clinical mycology, 2nd edn. Churchill Livingstone, Oxford, UK
21. Kaplan JE, Hanson DL, Navin TR, Jones JL (1998) Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 178:1126-1132
22. Kurokawa T, Hase M, Tokuman N, Yoshida T (2011) Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol 29:5-9. doi: 10.1002/hon.947
23. Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82:1052-1059. doi: 10.4065/82.9.1052
24. Martin SI, Fishman JA (2009) Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S227-S233. doi: 10.1111/j.1600-6143.2009.02914.x
25. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24:897-902. doi: 10.1038/sj.bmt.1702004